Business Valuation Methods: 2026 Guide for European Founders

Method 1: EBITDA multiples

EBITDA × multiple = enterprise value. From enterprise value, subtract net debt to get equity value, which is what shareholders actually receive. Multiples vary by sector, growth rate, customer concentration and recurring-revenue share. European mid-market manufacturing trades at 5–7× EBITDA in 2026, professional services at 4–6×, healthcare services at 8–11×, and B2B software at 10–15×.

Use normalized EBITDA — strip out owner's compensation above market rate, one-off legal costs, gains/losses on asset sales, and any related-party transactions. A 'quality of earnings' (QoE) report from a Big-4 or local fiduciary is standard for any deal above CHF 5M enterprise value and routinely adjusts reported EBITDA by 10–20%.

Method 2: Revenue multiples

When EBITDA is small, negative or unrepresentative (because the company is reinvesting heavily in growth), the market uses revenue multiples. Standard 2026 ranges for European businesses: e-commerce 0.5–1.5× revenue, SaaS 3–8× ARR, agencies 0.8–1.5× revenue, professional services 1–2× revenue, manufacturing 0.6–1.2× revenue.

Revenue multiples are most useful for SaaS, where forward ARR is highly predictable and gross margins are uniform. For physical-product companies, revenue multiples are crude — two distributors with identical revenue can have wildly different value if one has 30% gross margin and the other 8%.

Method 3: Discounted cash flow (DCF)

Project free cash flow for 5–10 years, calculate a terminal value, discount everything back to today at the weighted-average cost of capital (WACC). Add starting cash, subtract debt, and you have equity value. DCF is theoretically the most accurate method because it ties valuation directly to the cash the business produces.

The problem is sensitivity. A DCF with WACC of 11% produces a meaningfully different number than the same model at 12%. Terminal value typically represents 60–75% of the total DCF — meaning the long-term growth assumption (usually 2.0–2.5% in 2026) dominates the answer. Use DCF as a sense-check against multiple-based methods, not as the primary valuation when comparables exist.

Sector and country comparables in 2026

Switzerland generally trades at a 10–15% premium to French or Italian SME comps due to lower country risk and pension-fund demand for local mid-market deals. Germany sits between Switzerland and France. Italy carries a 10–20% discount for similar businesses, driven by working-capital risk and structural payment delays.

Sector premiums in 2026 favour cybersecurity (12–18× EBITDA), vertical SaaS (10–14×), specialty pharma services (10–13×), and recurring-revenue HVAC/facility services (8–10×). Cyclicals (construction, capital equipment, hospitality) trade at 4–6× and discount further during interest-rate cycles.

Founder valuation mistakes

Over-projecting the hockey stick. A 5-year forecast that triples revenue in years 4–5 with no operational milestones is dismissed in five seconds by any buyer. Defensible forecasts grow into capacity that already exists or has been concretely planned (hired, signed leases, signed contracts).

Refusing to normalize EBITDA downward. Owner-operators routinely take below-market salary or capitalise R&D that should be expensed. Buyers normalize. Sellers who fight every adjustment end DD with less goodwill and lower final price.

Anchoring on a single comparable. 'My friend sold his company for 12× EBITDA' is not a valuation basis. Real comparable analysis uses 8–15 transactions screened for size, sector and growth, with explicit adjustments for differences.